Oncology Clinical Trials is a department of Intermountain Cancer Services that is committed to improving the care and treatment for patients who are diagnosed with cancer by offering cancer research studies as an option to standard therapies.

Recently Approved Studies

Study Number: Impassion WO39391/BIG 16-05/AFT-27

Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti -Pd-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple Negative Breast Cancer

***ATEZOLIZUMAB is provided***

**Open at IMED and Dixie***

ASK YOUR DOCTOR

 

Study Number: A041501

Alliance A041501: A Phase III, Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL.

***INOTUZUMAB OZOGAMICIN is provided***

***Open at LDS Only***

ASK YOUR DOCTOR

 

Study Number: Replimune (RP1) / RPL-001-16

An Open-Label, Multicenter, Phase I/II Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors – Protocol RPL-001-16

***RP1 and NIVOLUMAB is provided***

***Open at DIXIE and IMC***

ASK YOUR DOCTOR

 

Study Number: MK-7339-002

Merck-002 A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

**OLAPARIB is provided***

**Open at DIXIE***

ASK YOUR DOCTOR

 

Study Number: NCT0344553

IDERA Illuminate A Randmized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimubab alone in Subjects with Anti-PD-1 Refractory Melanoma

***IMO-2125 is provided***

***Open at DIXIE and IMC***

ASK YOUR DOCTOR

 

Brain | Oncology Clinical Trials

Study Number: N0577 CTSU

Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

ASK YOUR DOCTOR

 

Breast | Oncology Clinical Trials

Study Number: Impassion WO39391/BIG 16-05/AFT-27

A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti -Pd-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple Negative Breast Cancer

***ATEZOLIZUMAB is provided***

***Open at IMED and Dixie***

ASK YOUR DOCTOR

 

Study Number: A221505

A Phase III Randomized Trial Of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

ASK YOUR DOCTOR

 

Study Number: A011202

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (CT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy.

**Temporarily Closed to Accrual**

 

Study Number: NSABP B51

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

ASK YOUR DOCTOR

 

Study Number: NRG BR003

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

ASK YOUR DOCTOR

 

Gastrointestinal | Oncology Clinical Trials

Study Number: COLOCARE

An international prospective cohort study of stage I-IV colorectal cancer patients.

***Open at LDS and IMC***

Temporarily on hold

ASK YOUR DOCTOR

 

Study Number: HIMALAYA NCT03298451

A randomized, Open-label Multicenter Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma NCT03298451

***DURVALUMAB, TREMELIMUMAB and SORAFENIB provided***

***Open at IMC Only***

ASK YOUR DOCTOR

 

Study Number: A021502

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

***ATEZOLIZUMAB provided***

Temporarily closed to accrual

 

Study Number: NRG GI002

NRG GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

***MK-3475 (PEMBROLIZUMAB) provided***

Temporarily closed to accrual

 

Genitourinary | Oncology Clinical Trials

Study Number: NRG GU006

Phase II Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer

***APALUTAMIDE provided***

ASK YOUR DOCTOR

 

Study Number: NRG GU005

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer

ASK YOUR DOCTOR

 

Study Number: NRG GU002

NRG GU002: Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel.

ASK YOUR DOCTOR

 

Head and Neck | Oncology Clinical Trials

Study Number: RTOG 1008

A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

ASK YOUR DOCTOR

 

Study Number: NRG HN001

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

ASK YOUR DOCTOR

 

Study Number: RTOG 1216

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Temporarily closed to accrual (eff 2/22/16)

 

Leukemia | Oncology Clinical Trials

Study Number: A041501

Alliance A041501: A Phase III, Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL.

***Inotuzumab Ozogamicin is provided***

***Open at LDS Only*** NCT03150693

ASK YOUR DOCTOR

 

Study Number: BMT CTN 1506 / Astellas 2215-CL-0304 (MORPHO)

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML NCT02997202

***Gilteritinib/Palcebo is provide***

***Open at LDS Only***

ASK YOUR DOCTOR

 

Study Number: Astellas 2215-CL-0201 (Lacewing)

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

***ASP2215 (GILTERITINIB) is provided***

***Open at LDS Only*** NCT02752035

ASK YOUR DOCTOR

 

Study Number: E1910

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative Acute Lymphoblastic Leukemia in Adults Blinatumomab is provided.

ASK YOUR DOCTOR

 

Bone Marrow Transplant | Oncology Clinical Trials

There are no studies to show

 

Lung | Oncology Clinical Trials

Study Number: CA209816 (CheckMate 816)

Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (Protocol CA209816) (CheckMate 816)

***NIVOLUMAB and IPILIMUMAB are provided***

***Open at IMC Only*** NCT02752035

ASK YOUR DOCTOR

 

Study Number: A081105

Randomized Study Of Erlotinib Or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) (An ALCHEMIST Treatment Trial)

***ERLOTINIB is provided***

ASK YOUR DOCTOR

 

Study Number: E4512

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (An ALCHEMIST Treatment Trial)

***CRIZOTINIB is provided***

ASK YOUR DOCTOR

 

Study Number: EA5142

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non- Small Cell Lung Canceers (An ALCHEMIST Treatment Trial)

***NIVOLUMAB is provided***NCT02648024

ASK YOUR DOCTOR

 

Study Number: STABLE-MATES

A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) - The STABLE-MATES Trial

***Open at IMC Only*** NCT02468024

ASK YOUR DOCTOR

 

Study Number: A151216

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

A screening trial for A081105, EA5142, and E4512

ASK YOUR DOCTOR

 

Lymphoma | Oncology Clinical Trials

Study Number: JUNO Transcend 017006

JUNO Transcend 017006: A Phase II Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-Cell NHL

***LISOCABTAGENE MARALEUCEL is provided***

***Open at LDS Only***

ASK YOUR DOCTOR

 

Study Number: JUNO Outreach 017007

JUNO Outreach 017007: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-Cell Non Hodgkin Lymphoma (NHL) in the Outpatient Setting

***LISOCABTAGENE MARALEUCEL is provided***

***Open at LDS Only***

ASK YOUR DOCTOR

 

Study Number: A051301

A051301: A randomized double blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-Cell lymphoma of the activated B-Cell subtype

***IBRUTINIB/PLACEBO is provided***

Temporarily closed to accrual

 

Melanoma | Oncology Clinical Trials

Study Number: Idera Illuminate

IDERA Illuminate A Randmized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimubab alone in Subjects with Anti-PD-1 Refractory Melanoma.

***IMO-2125 is provided***

***Open at IMC and Dixie*** NCT03445533

ASK YOUR DOCTOR

 

Study Number: Amgen Imlygic 20130193

A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients

***Open at IMC only***

ASK YOUR DOCTOR

 

Study Number: SWOG S1512

S1512 A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Primary Locally Advanced, Locally Recurrent or Metastatic Desmoplastic Melanoma (DM)

***MK-3475 PEMBROLIZUMAB is provided***

ASK YOUR DOCTOR

 

Study Number: Polynoma

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence

***Dr. Bowles Only*** NCT01546571

Temporarily closed to accrual

 

Study Number: Amgen Registry

A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects With Melanoma Who Previously Received Talimogene Laherparepvec – Protocol #20120139

***IMC ONLY*** Dr. Bowles Only NCT02173171

 

Miscellaneous Trials | Oncology Clinical Trials

Study Number: Replimune (RP1) / RPL-001-16

An Open-Label, Multicenter, Phase I/II Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors – Protocol RPL-001-16

***RP1 and NIVOLUMAB are provided***

***Open at IMC and Dixie*** NCT03445533

ASK YOUR DOCTOR

 

Study Number: MK-7339-002

Merck-002 A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

***OLlPARIB is provided***

***Open at Dixie*** NCT03742895

ASK YOUR DOCTOR

 

Study Number: SWOG S1415CD

SWOG S1415CD A Pragmatic Trial to Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia

***Open at Dixie, IMC, MKD, LOGAN

ASK YOUR DOCTOR

 

Study Number: NRG CC004

PHASE II DOUBLE BLIND DOSE FINDING TRIAL OF BUPROPION VERSUS PLACEBO FOR SEXUAL DESIRE IN WOMAN WITH BREAST OR GYNECOLOGIC CANCER

***BUPROPION is provided***

ASK YOUR DOCTOR

 

Study Number: DCP-001

DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

To be enrolled with select NCORP Studies

 

Study Number: SWOG S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

***NIVOLUMAB and IPILIMUMAB are provided***

ASK YOUR DOCTOR

 

Study Number: TAPUR

The Targeted Agent and Profiling Utilization Registry

***Open at IMC, Dixie and Cedar City*** NCT02693535

ASK YOUR DOCTOR

 

Myeloma | Oncology Clinical Trials

There are no studies to show

 

Sarcoma | Oncology Clinical Trials

There are no studies to show